CDEK
← All drugs Report issue

bone autograft

Cell therapyexperimental

Clinical trial activity

133 trials · 131 clinical orgs · 0 marketing orgs

Phase 1
34
Phase 2
99
Phase 3
35
Phase 4
3

Earliest trial started Apr 1, 1988 (NCT00002461)

Timeline

1980s

  1. Jan 1, 1988

    Earliest Phase 2 Sponsor(trial)

1990s

  1. Jan 1, 1990

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 1990

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • BloodTissue restoration

    Blood tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • aulogous bone
  • autogenous bone
  • autologous bone
  • autologous bone marrow
  • bone autograft

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07242729N/AFeb 1, 2025Federal University of Sao Paulo
NCT05517434Phase 2/Phase 3 (Phase 3)Oct 31, 2022The Cleveland Clinic, University of Toronto
NCT05507099Phase 2Aug 8, 2022Dr. G. Karmy Medicine Professional Corporation
NCT04475341N/ASep 1, 2020University of Amsterdam
NCT04205656Phase 1/Phase 2 (Phase 2)Jan 1, 2020Department of Defense, United States Navy
NCT03912454N/AApr 30, 2019Bone and Joint Clinic of Baton Rouge
NCT04559295Phase 2/Phase 3 (Phase 3)Nov 21, 2018Stem Cures
NCT03340818N/AJul 30, 2018APM Spine and Sports Physicians, Jordan Young Institute, Stanford University
NCT03876795Phase 3May 9, 2018University of Bologna
NCT02779374N/AJul 31, 2016South Valley University
NCT03110666Phase 4Jul 25, 2016University of Bologna
NCT02443077Phase 3Jul 6, 2016National Cancer Institute (NCI)
NCT02702960Phase 2Mar 1, 2016Fibrolamellar Cancer Foundation, Johns Hopkins University
NCT03110679Phase 4Feb 18, 2016University of Bologna
NCT02529839N/AOct 1, 2015Hebrew University
NCT02325843Phase 2Jul 31, 2015Sun Yat-Sen University, Xiamen University
NCT02240342N/ASep 30, 2014University of Valencia
NCT02011295N/AJan 29, 2014Duke University
NCT01536106Phase 1/Phase 2 (Phase 2)Dec 31, 2013Care Hospital, Hyderabad, Fortis Escorts Heart Institute and Research Centre, TotipotentRX
NCT02059681Phase 1Dec 31, 2013Azienda Ospedaliera San Gerardo di Monza, Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista, Centro Cardiologico Monzino IRCCS, University of Turin
Showing 20 of 133 trials
Page 1 / 7

Organizations

Research & Development (131)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government531141993
Cornell UniversityAcademic/Hospital10931992
Johns Hopkins UniversityAcademic/Hospital7531994
European Organisation for Research and Treatment of CancerAcademic/Hospital6621993
Eastern Cooperative Oncology GroupAcademic/Hospital5111993
Garden State Cancer CenterAcademic/Hospital5521997
New York UniversityAcademic/Hospital5331994
Cancer and Leukemia Group B (CALGB)Academic/Hospital4011994
City of Hope National Medical CenterAcademic/Hospital4331994
Herbert Irving Comprehensive Cancer CenterAcademic/Hospital4421996
Mayo ClinicAcademic/Hospital4221993
Southwest Oncology GroupAcademic/Hospital4211994
Temple UniversityAcademic/Hospital4411990
University of CincinnatiAcademic/Hospital4231990
University of Southern CaliforniaAcademic/Hospital4332000
Children's Cancer and Leukaemia GroupAcademic/Hospital3322001
Newcastle UniversityAcademic/Hospital3021994
Northwestern UniversityAcademic/Hospital3321999
University of BolognaAcademic/Hospital3322016
University of LondonAcademic/Hospital3021993
131 organizations
Page 1 / 7